Supplementary Materials

Supplementary Material for:

Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy

Sarah L. DeVos, Rebecca L. Miller, Kathleen M. Schoch, Brandon B. Holmes, Carey S. Kebodeaux, Amy J. Wegener, Guo Chen, Tao Shen, Hien Tran, Brandon Nichols, Tom A. Zanardi, Holly B. Kordasiewicz, Eric E. Swayze, C. Frank Bennett, Marc I. Diamond, Timothy M. Miller*

*Corresponding author. Email: miller.t{at}wustl.edu

Published 25 January 2017, Sci. Transl. Med. 9, eaag0481 (2017)
DOI: 10.1126/scitranslmed.aag0481

This PDF file includes:

  • Fig. S1. Human and murine tau mRNA in control-treated PS19 mice.
  • Fig. S2. ASOs are distributed throughout adult mouse brain.
  • Fig. S3. Human tau mRNA is decreased after TauASO-12 treatment in the 6- to 9-month-old prevention cohort and 9- to 12-month-old reversal cohort.
  • Fig. S4. Phosphorylated tau is reversed across multiple brain regions after reducing human tau.
  • Fig. S5. Human tau reduction reverses Thioflavin S–positive NFTs in the piriform cortex of aged PS19 mice.
  • Fig. S6. Astrogliosis is reduced after TauASO-12 treatment in aged PS19 mice.
  • Fig. S7. Reducing human tau prevents entorhinal cortex atrophy in aged PS19 mice.
  • Fig. S8. Reducing human tau prevents a reduction in cell size in the CA1 region of the hippocampus in aged PS19 mice.
  • Fig. S9. Correlation of total tau protein between brain and CSF in nonhuman primates.

[Download PDF]